Skip to main content

Radioligand Therapy Market Recent Industry Developments and Growth Strategies Adopted by Players with Revenue Insights


 

The global radioligand therapy market comprises well-established and newly emerging companies. . Several companies are attempting to sustain their position in the market by launching new products and raising funds to develop new products for the innovation in radioligand therapy from different sample types.

The global radioligand therapy market was valued at $9.75 billion in 2020 and is projected to reach $16.65 billion by 2031, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 4.67% during the forecast period 2021-2031.

Radioligand Therapy Market

In the comprehensive study of the global radioligand therapy market, BIS Research extensively covers the following:

  • Market numbers on micro-segments influencing the market
  • Market share analysis of key market players
  • Growth share analysis of companies
  • Impact of COVID-19 on the global radioligand therapy market
  • Growth analysis by indication, product, biomarker, and region
  • Detailed company and product profiling for 16 companies
  • Pipeline analysis for potential pipeline drugs
  • Market scenario for radioligand therapy marketed products and potential pipeline products
  • Drivers promoting the growth of the market
  • Emerging opportunities in the radioligand therapy market

Besides these parameters, the study also encompasses the market growth drivers, market restraining factors, opportunities, competition mapping, and segmental analysis.

BIS Research study indicates that the growing prevalence of cancer, strategic initiatives by key market players, and the rise in microbial sequencing are the major factors anticipated to contribute to the growth of the global radioligand therapy market.

The detailed study is a compilation of 07 market data tables and 138 figures spread through 182 pages and in-depth TOC on “Global Radioligand Therapy Market – Analysis and Forecast, 2021-2031”

USP of the Report

This extensive report can help in the following ways:

  • Aids in product development
  • Helps in targeting a segment for launching and approval of a new product
  • Offers go-to-market strategies for the different product categories
  • Supports diversifying the product portfolio based on unmet needs
  • Helps in analyzing technological substitutes and compares the specification
  • Helps to adjust the pricing of upcoming products
  • Assists in exploring the newer applications
  • Supports in analyzing the competitors’ funding scenario

 COVID-19 Impact on Global Radioligand Therapy Market

The global spread of COVID-19, caused by the novel coronavirus SARS-CoV-2, has resulted in a continuing pandemic threat to global health. Nuclear medicine techniques can be used for functional imaging of pathophysiological processes at the cellular level and for treatment approaches based on targeted delivery of therapeutic radionuclides. Ongoing development of radiolabeling methods has significantly improved the accessibility of radiopharmaceutical products for targeted radionuclide therapy, but their use for biosafety threats such as SARS-CoV-2 is restricted by the contagious nature of these agents.

Moreover, radioligand therapies rely on complex supply chains and advanced logistics. The lockdowns imposed by most countries and the closure of borders have generated shortages of radionuclides and other essential raw material supplies in many countries

Analyst’s Take on the Market:

According to Nitish Kumar Singh, Principal Analyst – BIS Research, “The reason for market growth can be attributed to the increasing prevalence of cancer, the rising strategic initiatives taken by key market players, and rising in clinical research activity. Biomarkers such as prostate-specific membrane antigen, Ki 67 Expression and Grading, Cytochrome P450 17a1 contain valuable information. Deciphering the expanding radiopharmaceuticals coverage provides an opportunity to develop radioligand therapy for the treatment of cancer, mainly prostate cancer.” Moreover, the use of radioligand to generate gastrin-releasing peptide receptors represents an emerging strategy in the drug discovery field. The approach offers improved affinity, stability, and cellular penetration. A captivating future of drug discovery is envisaged by the potential of potent breakthrough drugs that are no longer limited to extracellular or receptor targets. The utilization of radiopharmaceuticals for the design of gastrin-releasing radioligand peptide receptors can be a prominent and significantly lucrative approach to result in successful radioligand drug discovery.”


Who should buy this report?

  • Manufacturers of radioligand therapy-approved products and potential pipeline products
  • Pharmaceutical and biotechnology companies
  • Research and academic institutions


Key Questions Answered in the Report:

• How is radioligand therapy revolutionizing oncology?
• What are the major market drivers, challenges, and opportunities in the global radioligand therapy market?
• What are the underlying structures resulting in the emerging trends within the global radioligand therapy market?
• How is the COVID-19 pandemic impacting the global radioligand therapy ecosystem?
• What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of radioligand-targeted therapies?
• What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
• How is each market segment expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
o Products (Approved Products and Potential Pipeline)
o Indication (Prostate Cancer, Neuroendocrine Tumor (NETs), and Others)
o Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor)
o Region (North America, Europe, Asia-Pacific, and Rest-of-the-World)
• What are the growth opportunities for the radioligand therapy companies in the region of their operation?
• Who are the leading players with significant offerings in the global radioligand therapy market?
• Which companies are anticipated to be highly disruptive in the future, and why?


Get FREE Sample Report - https://bisresearch.com/requestsample?id=1280type=download

The scope of the report exclusively covers manufacturers offering proprietary radioligand therapy for target indications such as prostate cancer and neuroendocrine tumors. The study considers products based on various radioisotopes underlying applications in oncology to detect biomarkers and treatment of cancers. Moreover, the study considers the generics sales of Zytiga. 

Labels:

Comments

Post a Comment

Popular posts from this blog

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...
Post a Comment
Read more

Clinical Decision Support Systems (CDSS) Market registering a CAGR of 6.70% during the forecast period 2021-2030

The global market for clinical decision support systems (CDSS) registered the market value of $1,918.8 million in 2020 and is expected to reach $3,739.2 million by 2030, registering at a CAGR of 6.70% during the forecast period 2020-2030. The clinical decision support systems of the future are expected to be developed to leverage data to make observations which are not interpretable by humans. Healthcare IT systems in the future are expected to leverage cutting-edge technology as an enabler to make clinical care more streamlined and accurate. The technology is still in its nascent stage. One of the strong points of this technology is that it improves with time. Continuous input from clinicians, patients, and other stakeholders will be essential for correctly implementing the technology to enhance meaningful uses, reduce costs, and improve treatment outcomes. Key USPs of the Report Following are some of the key contents of the report: •     Industry Analysis    ...
Post a Comment
Read more

Hyperspectral Imaging Market Projections , Upcoming Trends Focus on Long-Term Impact of Covid-19 and Forecast By 2027

  The global  hyperspectral imaging market  was estimated to be at $791.2 million in 2021, which is expected to grow with a CAGR of 13.17% and reach $1,640.3 million by 2027.The growth in the global hyperspectral imaging market is expected to be primarily driven by increased awareness of the technology in different sectors such as agriculture, healthcare, and mining. The hyperspectral imaging technology has great potential, and the market is anticipated to grow during the forecast period owing to the widespread applications of HSI, increasing investments for RD activities, increasing demand from military and defense sectors, increased food safety concerns, and increasing awareness regarding early diagnosis of diseases.   COVID-19 Impact and Post-COVID-19 Scenario The COVID-19 pandemic had a debilitating impact on the global ecosystem. The pandemic led to a shutdown of production facilities, which do not come under essential goods, which led to a negative impact on se...
Post a Comment
Read more